Stock DGNS PT DIAGNOS LABORATORIUM UTAMA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Diagnos Laboratorium Utama Tbk

Equities

DGNS

ID1000158702

Healthcare Facilities & Services

End-of-day quote INDONESIA S.E.
Other stock markets
 23:00:00 07/05/2024 BST 		5-day change 1st Jan Change
310 IDR -0.64% Intraday chart for PT Diagnos Laboratorium Utama Tbk -8.82% +26.02%
03-04 PT Diagnos Laboratorium Utama Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 PT Diagnos Laboratorium Utama Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 931,250 305,000 307,500
Enterprise Value (EV) 1 892,275 287,726 350,273
P/E ratio 14.4 x 24.1 x -22.5 x
Yield - - -
Capitalization / Revenue 3.08 x 1.58 x 2.11 x
EV / Revenue 2.95 x 1.49 x 2.4 x
EV / EBITDA 10.4 x 11.6 x -97.2 x
EV / FCF -30.5 x -19.4 x -19.5 x
FCF Yield -3.28% -5.14% -5.13%
Price to Book 4.61 x 1.45 x 1.57 x
Nbr of stocks (in thousands) 1,250,000 1,250,000 1,250,000
Reference price 2 745.0 244.0 246.0
Announcement Date 05/04/22 30/03/23 04/03/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 38,553 51,338 183,171 302,182 192,886 145,696
EBITDA 1 12,827 14,628 69,043 86,042 24,834 -3,604
EBIT 1 12,418 13,174 66,986 81,227 15,439 -15,151
Operating Margin 32.21% 25.66% 36.57% 26.88% 8% -10.4%
Earnings before Tax (EBT) 1 12,228 12,643 66,975 83,279 17,333 -13,573
Net income 1 9,265 9,275 52,687 64,304 12,665 -13,656
Net margin 24.03% 18.07% 28.76% 21.28% 6.57% -9.37%
EPS 2 196.6 30.88 52.69 51.84 10.13 -10.92
Free Cash Flow 1 8,188 5,223 -17,491 -29,272 -14,799 -17,955
FCF margin 21.24% 10.17% -9.55% -9.69% -7.67% -12.32%
FCF Conversion (EBITDA) 63.84% 35.71% - - - -
FCF Conversion (Net income) 88.38% 56.32% - - - -
Dividend per Share - - - - - -
Announcement Date 14/12/20 14/12/20 01/04/21 05/04/22 30/03/23 04/03/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 1,584 - - - 42,773
Net Cash position 1 1,537 - 14,630 38,975 17,274 -
Leverage (Debt/EBITDA) - 0.1083 x - - - -11.87 x
Free Cash Flow 1 8,188 5,223 -17,491 -29,272 -14,799 -17,955
ROE (net income / shareholders' equity) 112% 31.1% 72.4% 42.7% 6.14% -6.73%
ROA (Net income/ Total Assets) 47.1% 19.7% 43.7% 27.1% 4% -3.7%
Assets 1 19,653 47,118 120,684 237,215 316,274 368,757
Book Value Per Share 2 332.0 46.50 99.10 161.0 168.0 156.0
Cash Flow per Share 2 38.40 1.390 16.50 35.80 22.40 8.200
Capex 1 3,837 2,782 5,864 67,841 34,853 38,324
Capex / Sales 9.95% 5.42% 3.2% 22.45% 18.07% 26.3%
Announcement Date 14/12/20 14/12/20 01/04/21 05/04/22 30/03/23 04/03/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
PT DIAGNOS LABORATORIUM UTAMA TBK Stock PT Diagnos Laboratorium Utama Tbk
+26.02% 24.12M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-16.58% 8.49B
RADNET, INC. Stock RadNet, Inc.
+58.90% 4.08B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.78% 2.42B
SYNLAB AG Stock SYNLAB AG
-10.33% 2.42B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-8.91% 2.33B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-2.53% 2.01B
FLEURY S.A. Stock Fleury S.A.
-19.90% 1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-38.30% 1.26B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+2.19% 1.07B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. DGNS Stock
  4. Financials PT Diagnos Laboratorium Utama Tbk